MedTrace Logo

A Trial Investigating the Relationship Between Pharmacodynamic and Interstitial Concentration for Insulin Detemir and Human Insulin

NCT02162407 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2014-06-12

No results posted yet for this study

Summary

This study is conducted in Europe. The aim of this study is to estimate the relationship between pharmacodynamic and interstitial pharmacokinetic steady state following intravenous (i.v.) administration of insulin detemir and human soluble insulin.

Conditions

Interventions

DRUG

insulin detemir

Given as intravenous infusion (i.v.) over a period of 8 hours during euglycaemic clamp

DRUG

human soluble insulin

Given as intravenous infusion (i.v.) over a period of 8 hours during euglycaemic clamp

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-10-31
Primary Completion
1999-12-31
Completion
1999-12-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02162407 on ClinicalTrials.gov